Turns Out, It Wasn't Bad News for Intra-Cellular Therapies [The Motley Fool]
Intra-Cellular Therapies Inc. (ITCI)
Last intra-cellular therapies inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intracellulartherapies.com/investor-relations
Company Research
Source: The Motley Fool
Turns Out, It Wasn't Bad News for Intra-Cellular Therapies Down over 18%, the biotech bounces back. The Food and Drug Administration told Intra-Cellular Therapies ( NASDAQ:ITCI ) that it doesn't plan to hold an advisory committee meeting to review Intra-Cellular's marketing application for lumateperone as a treatment of schizophrenia. There's two ways to interpret that: Investors seem to have had both opinions today, having sent shares down over 18%, only to bid them back up into the black. The FDA had previously scheduled an advisory committee meeting for the end of July, but the agency canceled it after Intra-Cellular submitted additional nonclinical information. At the time, Intra-Cellular said the FDA canceled that meeting "to allow sufficient time to review this new and any forthcoming information." Intra-Cellular submitted even more nonclinical results that the FDA asked for. The company thinks the data support the idea that animals and humans metabolize the drug differently, s
Show less
Read more
Impact Snapshot
Event Time:
ITCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITCI alerts
High impacting Intra-Cellular Therapies Inc. news events
Weekly update
A roundup of the hottest topics
ITCI
News
- Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data [Seeking Alpha]Seeking Alpha
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $82.00 price target on the stock.MarketBeat
- Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive DisorderGlobeNewswire
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $82.00 price target on the stock.MarketBeat
ITCI
Earnings
- 2/22/24 - Beat
ITCI
Sec Filings
- 4/16/24 - Form 8-K
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- ITCI's page on the SEC website